Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Prospect Capital Corporation (PSEC) Price & Performance

Bristol-Myers Squibb CoTrade
Prospect Capital CorporationTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Prospect Capital Corporation — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while Prospect Capital Corporation trades at $2.29 (market cap $1.14B). The key difference: Bristol-Myers Squibb Co is far larger — about 114× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (21.93%). Which is the better fit depends on your goals.

BMYPSEC
Market Cap
$129.94B$1.14B
Sector
HealthFinancials
52-Week High
$65.89$3.05
52-Week Low
$42.60$2.11
Enterprise Value
$163.92B
Dividend Yield
3.96%21.93%

Returns comparison

Trailing returns across standard periods

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Prospect Capital Corporation

Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.

Read more on PSEC